World Market for Prescription Generic Drugs

6th Edition

Publication Date	April 2008
Publisher	Kalorama Information
Product Type	Report
Pages	250
ISBN Number	not applicable
Product Code	KAL00114

Buy this product or for assistance call +44 20 7060 7474

PDF £2,400.00$3992 | €2686

PRINT £2,640.00$4391 | €2955

FAX Order above formats by FAX

Summary

Generics, so long the force that has shaken up the branded pharmaceutical industry, is now facing its own challenges as an industry. While growth indications are strong, there are challenges for generic companies. In the next two years, consolidation will most likely rise; the sector is expected to be rocked by increased competition from companies in Eastern Europe, India and China, as well as brand name companies seeking to protect their franchises by moving into generics.

Kalorama Information's World Market for Prescription Generic Drugs, 6th Edition is your guide to this formidable and important participant in the complex world of healthcare. Included are market size and forecast revnues for:

Allergy and Respiaratory Drugs
Analgesics, NAIDS, and Antirheumatic Drugs
Anesthesia Drugs
Anti-Infectives
Cancer Drugs
Cardiovascular Drugs
Central Nervous System and Psychotherapeutic Drugs
Gastrointestinal Drugs
Ophthalmic Drugs

This report is the result of primary research and secondary research. Interviews with experts in the generic industry form the basis of this report. Research was conducted from available company reports, trade publications and medical and government databases. Interviews with experts are the source of models.

For each drug segment, the report provides:

Estimated Generic Market Size
Forecast to 2012
Recent ANDA Approvals
World and US Market Share
Company Profiles
Knowledge of the i

ssues that face the generics industry is essential to understanding the market. The report discusses the following trends:

Legislative Issues
Big Pharma Tactics
Authorized Generics
Generic Biologics
Medicaid Generic Drug Reimbursement
The Elderly
Confusion in Generic Names
Broadening Generic Horizons
International Generic Drug Issues
Indian Drug Makers
Industry Consolidation
New Generic Giants
Patent Issues
Generic Companies Increasingly Aggressive
Patent Reform
Generic Growth
Generic Statins
Cost
Generics Improve Compliance
Generic Drug Sampling

Marketing executives, business development managers and brand and generic pharmaceutical companies, consultants and investors are among those who will benefit from this report.

Content

Chapter One: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Trends Affecting the Market
- Market Outlook
Chapter Two:Introduction
- Industry Development
- Generic Drug Industry Evolution
- FDA Regulation
- Development and Approval Process
- Industry Structure
- Product Distribution
- Patent Expirations
Chapter Three: Allergy and Respiratory Drugs
- Product Categories
- Asthma, Bronchodilators and Corticosteroids
- Inhaled Corticosteroids
- Antiasthmatic Agents
- Bronchodilating Agents
- Antihistamines, Decongestants, and Cough Preparations
- Antihistamines
- Decongestants
- Cough Preparations
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs World Market
- Competitive Analysis
Chapter Four: Analgesics, Nonsteroidal
- ANTI-INFLAMMATORY DRUGS, AND ANTIRHEUMATIC DRUGS
- Product Categories
- Analgesics
- Nonsteroidal Anti-inflammatory Drugs
- Antirheumatics
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs World Market
- Competitive Analysis
Chapter Five: Anesthesia Drugs
- Product Categories
- General
- Local
- Regional
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs World Market
Chapter Six: Anti-Infectives
- Product Categories
- Systemic Anti-Infectives
- Topical Anti-Infectives
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs World Market
- Competitive Analysis
Chapter Seven: Cancer Drugs
- Products
- Product News
- Market Size and Forecast
- The World Marke
- The U.S. vs World Market
- Competitive Analysis
Chapter Eight: Cardiovascular Drugs
- Product Categories
- Positive Inotropic Agents
- Antiadrenergics
- Beta-Adrenergic Blocking Agents
- Vasodilators
- Calcium Channel Blockers
- Angiotensin-Converting Enzyme Inhibitors
- Antiarrhythmics
- Antihyperlipidemic Agents
- Anticoagulants
- Diuretics
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs. World Market
- Competitive Analysis
Chapter Nine: Central Nervous System and
- PSYCHOTHERAPEUTIC DRUGS
- Product Categories
- Antidepressants, Stimulants, and Antipsychotics
- Antidepressants
- Stimulants
- Antipsychotics
- Anticonvulsants, Antispasmodics, and Muscle Relaxants
- Anticonvulsants
- Antispasmodics
- Muscle Relaxants
- Parkinson's Disease, Myasthenia Gravis, and Multiple Sclerosis
- Parkinson's Disease
- Myasthenia Gravis
- Multiple Sclerosis
- Sedatives, Hypnotics, and Antianxiety Drugs
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs World Market
- Competitive Analysis
Chapter Ten: Gastrointestinal Drugs
- Product Categories
- Antidiarrheals
- Antinauseants
- Antispasmodics
- Antiulcer
- Digestants
- Product News
- Market Size and Forecast
- The World Market
- The U.S. vs the World Market
- Competitive Analysis
Chapter Eleven: Hormonal Drugs
- Product Categories
- Male and Female Hormones
- Bone Metabolism Regulators
- Corticosteroids
- Diabetes Drugs
- Thyroid Drugs
- Product News
- Market Size and Forecast
- The World Market
- U.S. vs World Market
- Competitive Analysis
Chapter Twelve: Ophthalmic Drugs
- Product Categories
- Ophthalmic Anti-Infectives
- Ophthalmic Anti-Inflammatories and Mast Cell Inhibitors
- Glaucoma Agents
- Product News
- Market Size and Forecast
- The World Market
- U.S. vs World Market
- Competitive Analysis
Chapter Thirteen: World Market Summary
- Overview
- Total Market Size and Forecast
- Market and Competitive Analysis
Chapter Fourteen: Issues and Trends
- Understanding Hatch-Waxman and Its Shortfalls
- The FDA, Funding and Review times
- Big Pharma Tactics-Defensive and Offensive
- Authorized Generics
- Generic Biologics
- Medicaid Generic Drug Reimbursement Issues
- The Elderly
- Confusion in Generic Drug Names
- Broadening Generic Horizons
- International Generic Drug Issues
- Indian Drug Makers
- Industry Consolidation
- New Generic Giants
- Patent Issues: Filings and Challenges
- Generic Companies Increasingly Aggressive
- Patent Reform
- Generic Growth: Prescriptions, Approvals, Impact
- Generic Statins Countdown
- Prescription Drug Costs
- Generics Improve Compliance
- Generic Drug Sampling
Chapter Fifteen: Company Profiles
- Industry Structure and Participants
- Actavis Group
- APOTEX, Inc.
- Aurobindo Pharma, Ltd
- Barr Laboratories, Inc.
- Bedford Laboratories
- Dr Reddy's Laboratories Limited
- Dragon Pharmaceuticals, Inc.
- Hospira Inc.
- Mylan Laboratories, Inc.
- Orchid Chemicals and Pharmaceuticals, Ltd.
- Par Pharmaceuticals, Inc.
- Perrigo Company
- PLIVA Pharmaceuticals, Inc.
- Ranbaxy Laboratories, Ltd.
- Roxane Laboratories, Inc.
- Sandoz
- Taro Pharmaceutical Industries Ltd.
- TEVA Pharmaceutical Industries, Ltd.
- Watson Pharmaceuticals, Inc.
- United Research Laboratories and Mutual Pharmaceutical Company
- Zydus Pharmaceuticals, Inc.
- APPENDIX: COMPANY DIRECTORY